The Opioid Crisis by the Numbers: Latest Data & Trends

Overdose death trends, national and regional

The United States has now recorded several consecutive years of improvement after overdose mortality reached historic levels. Final National Center for Health Statistics data show that the overall age-adjusted overdose death rate declined from 32.6 per 100,000 in 2022 to 31.3 in 2023 and 23.1 in 2024. Opioid-involved deaths fell particularly sharply in 2024, from 79,358 to 54,045. For wider context, the CDC estimates that approximately 806,000 people died from opioid overdoses between 1999 and 2023.

National improvement is not geographically uniform. In final 2024 all-drug data, West Virginia had the country’s highest state overdose death rate at 48.9 per 100,000, while the District of Columbia recorded 43.2. Nebraska had the lowest state rate at 8.1. These are age-adjusted rates, which make population comparisons more useful, but they do not account for every social, economic or healthcare difference between places.

Provisional 2025 data showed decreases in almost every state, with declines of at least 25% in Rhode Island, New York, North Carolina, Alabama and Vermont. New Mexico, Arizona and Colorado moved in the opposite direction, each recording an increase of at least 10% in the provisional comparison. This uneven pattern means a falling national total can coexist with serious local deterioration. Readers comparing these figures with broader substance-use trends may also find Addiction & Rehab Statistics 2026: The Complete Data Report useful.

Fentanyl's role in the current crisis

Fentanyl remains the defining drug of the current phase of the opioid crisis. The CDC describes the epidemic as three overlapping waves: prescription opioids beginning in the 1990s, rapidly rising heroin deaths from around 2010, and synthetic opioid deaths led by illegally manufactured fentanyl from 2013 onward. Pharmaceutical fentanyl has legitimate medical uses, but the CDC reports that most fentanyl-related harm is now connected to illegally made products.

Final drug-specific data identified fentanyl, fentanyl analogues or fentanyl metabolites in 47,452 overdose deaths in 2024, down from 73,376 in 2023. The closely related death-certificate category of synthetic opioids other than methadone accounted for 47,735 deaths in 2024. The two totals differ slightly because the CDC uses different identification methods, but both show the same picture: fentanyl was involved in roughly seven out of every eight opioid overdose deaths that year, even after a major decline.

• Fentanyl is approximately 50 to 100 times more potent than morphine, according to the CDC.
• Illegally manufactured fentanyl may appear in powders or counterfeit tablets and may be mixed with heroin, cocaine or methamphetamine.
• CDC surveillance found illegally manufactured fentanyls in 81.5% of overdose deaths in participating Northeast jurisdictions, 75.4% in the Midwest and 74.9% in the South during January 2021–June 2024.
• In the West, the percentage of overdose deaths with illegally manufactured fentanyls detected rose from 48.5% in early 2021 to 66.5% in April–June 2024.
• Final 2024 regional data showed the highest fentanyl-involved death rate among HHS regions in Region 10—Alaska, Idaho, Oregon and Washington—at 24.1 per 100,000.

The latest fentanyl overdose statistics therefore show two truths at once: fentanyl deaths are falling nationally, but the substance remains widespread and regional markets continue to change. Counterfeit pills and unexpected opioid contamination also mean that some people may be exposed without intending to take an opioid. See Fentanyl Addiction: What You Need to Know and Opioid Addiction: Signs, Symptoms & Treatment for more information about risks and treatment.

The treatment-access gap for opioid use disorder

Falling mortality has not closed the treatment gap. SAMHSA’s 2024 National Survey on Drug Use and Health estimated that 4.8 million people aged 12 or older had opioid use disorder in the previous year. Only 17%, or approximately 818,000 people, reported receiving medication for opioid use disorder during that period. In other words, roughly five out of six people in the survey’s OUD population did not report receiving this form of treatment.

Access is shaped by more than whether a treatment centre exists. People may face cost or insurance restrictions, long travel distances, limited appointment capacity, stigma, unstable housing, childcare or employment conflicts, and difficulty moving from an emergency department or detox service into continuing care. Methadone has additional access constraints because, except in limited circumstances, it must be dispensed through a federally certified opioid treatment program.

Treatment also needs to match clinical circumstances. Some people require supervised withdrawal management, while others can begin medication through outpatient, primary-care or emergency services. Residential treatment may be appropriate when medical, psychiatric or social needs call for greater structure, but it should not automatically interrupt effective OUD medication. The Levels of Care in Addiction Treatment: Detox to Aftercare, Medical Detox: What to Expect and Inpatient vs Outpatient Rehab: Which Is Right for You? guides explain these pathways in more detail.

Affordability remains part of access. Coverage varies by plan, provider and state, so families may need to review Does Insurance Cover Rehab? Complete Guide, Does Medicaid or Medicare Cover Rehab? or Free & Low-Cost Rehab Options Near You. An admissions team can confirm whether a facility offers or continues medication for opioid use disorder rather than requiring patients to stop it.

MAT utilization data

Medication-assisted treatment, commonly shortened to MAT, is increasingly called medication for opioid use disorder, or MOUD. The newer term emphasizes that medication is treatment in its own right and can be combined with counselling, peer support, mental healthcare and practical recovery services according to the person’s needs. The FDA has approved three medications for OUD: methadone, buprenorphine and naltrexone.

A pooled SAMHSA analysis of the 2022–2024 surveys found that 19.4% of approximately five million adults with past-year OUD received MOUD. Utilization varied markedly by age: 11.7% of adults aged 18–25 and 9% of adults aged 50 or older received medication, compared with 33.1% of adults aged 26–49. These differences help identify groups for whom outreach, screening and linkage to care may need strengthening.

NIDA-supported research also shows why the point of entry matters. In a randomized emergency-department study highlighted by NIDA, about 80% of participants offered ED-initiated buprenorphine and a brief intervention were engaged in treatment after 30 days—approximately twice the proportion in referral-focused groups. National utilization remains low, however, showing that evidence-based clinical models do not automatically become widely available.

Medication choice, timing and dose should be determined with a qualified clinician. Starting buprenorphine or naltrexone at the wrong point can trigger withdrawal, while abruptly stopping methadone or buprenorphine can increase risk. Speak with a doctor or clinical admissions team before changing treatment. The Medication-Assisted Treatment (MAT) Explained guide provides a fuller overview.

Policy responses and their measured impact

Federal and state responses have increasingly focused on naloxone access, insurance coverage and reducing regulatory barriers to OUD medication. Measuring the impact of any single policy is difficult because drug supply, treatment availability, local implementation and population conditions change at the same time. The strongest reading of the evidence is therefore that several interventions can contribute to improvement, rather than that one law caused the national decline.

The decline in deaths during 2024 and 2025 occurred after multiple expansions in naloxone distribution, MOUD access and flexible treatment delivery. It may also reflect changes in the unregulated drug supply and patterns of exposure. Current surveillance cannot assign a precise share of the decline to each factor, and the increases seen in several western states show how quickly conditions can diverge.

For individuals and families, policy becomes meaningful only when it produces practical access: naloxone nearby, an appointment without a long delay, medication that can be continued, and affordable ongoing care. When comparing providers, ask directly whether they initiate or maintain all appropriate OUD medications and how they coordinate follow-up. How to Choose a Rehab Center: 10 Questions to Ask and Aftercare Planning: Life After Rehab can help with those conversations.